valproic acid has been researched along with Angelman Syndrome in 8 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Angelman Syndrome: A syndrome characterized by multiple abnormalities, MENTAL RETARDATION, and movement disorders. Present usually are skull and other abnormalities, frequent infantile spasms (SPASMS, INFANTILE); easily provoked and prolonged paroxysms of laughter (hence happy); jerky puppetlike movements (hence puppet); continuous tongue protrusion; motor retardation; ATAXIA; MUSCLE HYPOTONIA; and a peculiar facies. It is associated with maternal deletions of chromosome 15q11-13 and other genetic abnormalities. (From Am J Med Genet 1998 Dec 4;80(4):385-90; Hum Mol Genet 1999 Jan;8(1):129-35)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The onset of epilepsy is most prevalent between 1 and 3 years of age; however, approximately 25% of patients developed epilepsy before one year of age." | 2.72 | Epilepsy in Angelman syndrome: A scoping review. ( Samanta, D, 2021) |
| "Angelman syndrome is a neurogenetic disorder caused by lack of UBE3A gene expression from the maternally inherited chromosome 15 due to various 15q11-q13 abnormalities." | 2.44 | Epilepsy in Angelman syndrome. ( Boyd, SG; Cheron, G; Dan, B; Pelc, K, 2008) |
| "Epilepsy was controlled with valproate at the age of 6 years." | 2.42 | A study of EEG and epilepsy profile in Wolf-Hirschhorn syndrome and considerations regarding its correlation with other chromosomal disorders. ( Fiore, LA; Freitas, A; Kim, CA; Valente, KD, 2003) |
| "After several years without seizures, 24 out of 30 had a relapse, which was quickly stopped in 23 out of 30 patients." | 1.72 | [Epilepsy in Angelman syndrome]. ( Bobylova, MY; Glukhova, LY; Kuzmich, GV; Mukhin, KY; Pylayeva, OA, 2022) |
| "Epilepsy was most common among those with maternal deletions and unknown subtypes, with catastrophic epilepsies present in only these two subtypes." | 1.35 | Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. ( Braun, EK; Bruno, P; Conant, KD; Nespeca, MP; Said, RR; Thibert, RL; Thiele, EA, 2009) |
| "A 25-year-old girl with mild mental retardation had a 6-year history of absence seizures, with occasional head drop." | 1.31 | Mild generalized epilepsy and developmental disorder associated with large inv dup(15). ( Canevini, MP; Canger, R; Cavani, S; Chifari, R; Elia, M; Guerrini, R; Pierluigi, M; Sgrò, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bobylova, MY | 1 |
| Mukhin, KY | 1 |
| Kuzmich, GV | 1 |
| Glukhova, LY | 1 |
| Pylayeva, OA | 1 |
| Ascoli, M | 1 |
| Elia, M | 2 |
| Gasparini, S | 1 |
| Bonanni, P | 1 |
| Mastroianni, G | 1 |
| Cianci, V | 1 |
| Neri, S | 1 |
| Pascarella, A | 1 |
| Santangelo, D | 1 |
| Aguglia, U | 1 |
| Ferlazzo, E | 1 |
| Samanta, D | 1 |
| Jamal, I | 1 |
| Kumar, V | 1 |
| Vatsa, N | 1 |
| Shekhar, S | 1 |
| Singh, BK | 1 |
| Sharma, A | 1 |
| Jana, NR | 1 |
| Thibert, RL | 1 |
| Conant, KD | 1 |
| Braun, EK | 1 |
| Bruno, P | 1 |
| Said, RR | 1 |
| Nespeca, MP | 1 |
| Thiele, EA | 1 |
| Chifari, R | 1 |
| Guerrini, R | 1 |
| Pierluigi, M | 1 |
| Cavani, S | 1 |
| Sgrò, V | 1 |
| Canger, R | 1 |
| Canevini, MP | 1 |
| Valente, KD | 1 |
| Freitas, A | 1 |
| Fiore, LA | 1 |
| Kim, CA | 1 |
| Pelc, K | 1 |
| Boyd, SG | 1 |
| Cheron, G | 1 |
| Dan, B | 1 |
4 reviews available for valproic acid and Angelman Syndrome
| Article | Year |
|---|---|
Therapeutic approach to neurological manifestations of Angelman syndrome.
Topics: Angelman Syndrome; Anticonvulsants; Epilepsy; Epilepsy, Generalized; Humans; Valproic Acid | 2022 |
Epilepsy in Angelman syndrome: A scoping review.
Topics: Angelman Syndrome; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Femal | 2021 |
A study of EEG and epilepsy profile in Wolf-Hirschhorn syndrome and considerations regarding its correlation with other chromosomal disorders.
Topics: Angelman Syndrome; Anticonvulsants; Child; Chromosome Deletion; Chromosome Disorders; Chromosomes, H | 2003 |
Epilepsy in Angelman syndrome.
Topics: Angelman Syndrome; Electroencephalography; Epilepsy; Humans; Valproic Acid | 2008 |
4 other studies available for valproic acid and Angelman Syndrome
| Article | Year |
|---|---|
[Epilepsy in Angelman syndrome].
Topics: Angelman Syndrome; Anticonvulsants; Child; Electroencephalography; Epilepsy; Ethosuximide; Female; H | 2022 |
Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.
Topics: Angelman Syndrome; Animals; Anxiety; Brain; Cell Line, Transformed; Cognition Disorders; Disease Mod | 2017 |
Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options.
Topics: Adolescent; Adult; Angelman Syndrome; Anticonvulsants; Child; Child, Preschool; Clonazepam; Comorbid | 2009 |
Mild generalized epilepsy and developmental disorder associated with large inv dup(15).
Topics: Adult; Age of Onset; Angelman Syndrome; Anticonvulsants; Chromosome Aberrations; Chromosome Inversio | 2002 |